Dexcom G6 持续葡萄糖监测在非重症住院糖尿病患者中的准确性
本研究分析三项住院 CGM 研究中 Dexcom G6 与床旁毛细血管血糖的配对数据,共纳入 218 例胰岛素治疗的糖尿病患者(96% 为 2 型糖尿病),总体 MARD 为 12.8%,98.7% 的 CGM 值位于 Clarke 误差网格 A 区和 B 区,提示 CGM 是可靠的住院血糖监测工具。
要点
- Dexcom G6 在非重症住院糖尿病患者中总体 MARD 为 12.8%,中位 ARD 为 10.1%。
- 93.8% 的读数满足 %30/30 标准,98.7% 的 CGM 值位于 Clarke 误差网格 A 区和 B 区。
- 低血糖(<70 mg/dL)和严重贫血(血红蛋白 <7 g/dL)时 MARD 和中位 ARD 更高。
核心结论
- CGM 技术是可靠的住院使用工具,可能有助于改善非重症住院糖尿病患者的血糖监测。
研究设计与样本
- 回顾性匹配配对分析,数据来自三项住院 CGM 研究(两项干预性和一项观察性),纳入 218 例接受胰岛素治疗的普通内科和外科糖尿病患者。
- 共分析 4067 对匹配的 CGM 与床旁毛细血管血糖数据。
主要发现
- 总体 MARD 为 12.8%,中位 ARD 为 10.1%(四分位距 4.6,17.6)。
- 满足 %15/15、%20/20 和 %30/30 标准的读数比例分别为 68.7%、81.7% 和 93.8%。
- Clarke 误差网格分析显示 98.7% 的值位于 A 区和 B 区。
- 低血糖(<70 mg/dL)和严重贫血(血红蛋白 <7 g/dL)时 MARD 和中位 ARD 更高。
临床怎么用
- Dexcom G6 可用于非重症住院糖尿病患者的血糖监测,但需注意低血糖和严重贫血时准确性下降。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Advances in continuous glucose monitoring (CGM) have transformed ambulatory diabetes management. Until recently, inpatient use of CGM has remained investigational, with limited data on its accuracy in the hospital setting. RESEARCH DESIGN AND METHODS: To analyze the accuracy of Dexcom G6, we compared retrospective matched-pair CGM and capillary point-of-care (POC) glucose data from three inpatient CGM studies (two interventional and one observational) in general medicine and surgery patients with diabetes treated with insulin. Analysis of accuracy metrics included mean absolute relative difference (MARD), median absolute relative difference (ARD), and proportion of CGM values within 15, 20, and 30% or 15, 20, and 30 mg/dL of POC reference values for blood glucose >100 mg/dL or ≤100 mg/dL, respectively (% 15/15, % 20/20, % 30/30). Clinical reliability was assessed with Clarke error grid (CEG) analyses. RESULTS: A total of 218 patients were included (96% with type 2 diabetes) with a mean age of 60.6 ± 12 years. The overall MARD (n = 4,067 matched glucose pairs) was 12.8%, and median ARD was 10.1% (interquartile range 4.6, 17.6]. The proportions of readings meeting % 15/15, % 20/20, and % 30/30 criteria were 68.7, 81.7, and 93.8%, respectively. CEG analysis showed 98.7% of all values in zones A and B. MARD and median ARD were higher in the case of hypoglycemia (<70 mg/dL) and severe anemia (hemoglobin <7 g/dL). CONCLUSIONS: Our results indicate that CGM technology is a reliable tool for hospital use and may help improve glucose monitoring in non-critically ill hospitalized patients with diabetes.
引用
- Davis GM, Spanakis EK, Migdal AL, et al. Accuracy of Dexcom G6 Continuous Glucose Monitoring in Non-Critically Ill Hospitalized Patients With Diabetes. Diabetes Care. 2021. PMID: 34099515. doi:10.2337/dc20-2856
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。